Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics, Inc. - Common Stock
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
↗
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
August 09, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
8 Analysts Have This to Say About Karuna Therapeutics
↗
August 09, 2022
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:
Via
Benzinga
Karuna Therapeutics: Q2 Earnings Insights
↗
August 08, 2022
Karuna Therapeutics (NASDAQ:KRTX) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
SVB Likes This 'Novel Antipsychotic'-Focused Stock
↗
July 14, 2022
Via
Benzinga
JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock
↗
June 28, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
↗
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
↗
August 09, 2022
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Via
Benzinga
GameStop, Signify Health And Some Other Big Gainers From Monday
↗
August 09, 2022
U.S. stocks closed mixed on Monday. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Analyst Ratings for Karuna Therapeutics
↗
June 28, 2022
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:
Via
Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
↗
August 09, 2022
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
Via
Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 08, 2022
Via
Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Nasdaq Turns Lower; Crude Oil Rises Over 1%
↗
August 08, 2022
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
August 08, 2022
Via
Benzinga
Karuna Therapeutics (NASDAQ: KRTX) Reports Positive Primary and Secondary Endpoint Results from Phase 3 EMERGENT-2 Clinical Trial of KarXT for Treating Schizophrenia
August 08, 2022
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is engaged as a clinical-stage biopharmaceutical company that is focused on the research and development
Via
Spotlight Growth
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
August 08, 2022
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6...
Via
Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data
↗
August 08, 2022
Karuna Therapeutics (KRTX) stock is rocketing higher on Monday thanks to results from a Phase 3 EMERGENT-2 trial to treat schizophrenia.
Via
InvestorPlace
Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win
↗
August 08, 2022
Karuna Therapeutics easily beat expectations for its midstage test in schizophrenia.
Via
Investor's Business Daily
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
Karuna Therapeutics Shares Surge After Encouraging Data From Schizophrenia Candidate
↗
August 08, 2022
Karuna Therapeutics Inc (NASDAQ: KRTX) has
Via
Benzinga
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 04, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022
↗
July 14, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
↗
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
June 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
↗
May 26, 2022
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.